About
Check out
the latest news
Featured
-
Ritalin, the brand name for methylphenidate, is a central nervous system stimulant widely recognized for its role in managing attention deficit hyperactivity disorder (ADHD) and, in some cases, narcolepsy. In the United Kingdom, its use is tightly regulated due to its potential for misuse and dependence, reflecting a balance between therapeutic access and public safety. […]
Highlighted
-
Ritalin, the brand name for methylphenidate, is a central nervous system stimulant widely recognized for its role in managing attention deficit hyperactivity disorder (ADHD) and,…
-
Atomoxetine, commonly known by its brand name Strattera, is a non-stimulant medication primarily prescribed for attention deficit hyperactivity disorder (ADHD). As a selective norepinephrine reuptake…
-
Solriamfetol in the USA is marketed under the brand name Sunosi, represents a significant advancement in treating excessive daytime sleepiness associated with sleep disorders. As…
-
Vyvanse, the brand name for lisdexamfetamine dimesylate, is a central nervous system stimulant widely used to manage attention deficit hyperactivity disorder (ADHD). As a prodrug…
-
Atomoxetine in the USA, best known under the brand name Strattera, has become a widely recognized non-stimulant option for managing attention-deficit/hyperactivity disorder (ADHD) in the…
-
As of today, pitolisant (commonly marketed under names such as Wakix) is not approved for medical use in Australia. While it has secured regulatory approval…